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SUMMARY
Cancer stem cells promote neoplastic growth, in
part by deregulating asymmetric cell division and
enhancing self-renewal. To uncover mechanisms
and potential therapeutic targets in glioma stem
cell (GSC) self-renewal, we performed a genetic sup-
pressor screen for kinases to reverse the tumor
phenotype of our Drosophila brain tumor model
and identified dCdk5 as a critical regulator. CDK5,
the human ortholog of dCdk5 (79% identity), is aber-
rantly activated in GBMs and tightly alignedwith both
chromosome 7 gains and stem cell markers affecting
tumor-propagation. Our investigation revealed that
pharmaceutical inhibition of CDK5 prevents GSC
self-renewal in vitro and in xenografted tumors, at
least partially by suppressing CREB1 activation inde-
pendently of PKA/cAMP. Finally, our TCGA GBM
data analysis revealed that CDK5, stem cell, and
asymmetric cell division markers segregate within
non-mesenchymal patient clusters, which may indi-
cate preferential dependence on CDK5 signaling
and sensitivity to its inhibition in this group.
INTRODUCTION
Cancer stem cells possess self-renewal properties, yet differ
from normal stem cells by their genetic instability and deregu-
lated asymmetric division, which together enhance self-renewal
and clonal proliferation (Mukherjee and Brat, 2017; Zabala et al.,
2016). Core regulators of asymmetric cell division have been well
described in Drosophila and many have mammalian orthologs
with similar functions (Mukherjee and Brat, 2017). Asymmetric
cell division mechanisms have also been investigated in the
context of neoplastic diseases (Mukherjee et al., 2015). In our
lab, we have successfully translated the Drosophila brain tumor
model to disrupted asymmetric cell division in human brain tu-
mors in order to uncover mechanisms and potential therapeutic
targets relevant to glioblastoma (GBM), World Health Organiza-
tion (WHO) grade IV (Mukherjee et al., 2016).
GBMs are a deadly form of brain tumor that are highly hetero-
geneous and include tumor cell clones with divergent genetic al-
terations and differentiation programs. Glioma stem cells (GSCs)
are a small, but biologically critical GBM subpopulation that con-
trol growth and differentiation dynamics (Liebelt et al., 2016;
Osuka and Van Meir, 2017). GSCs, often identified by their
expression of CD133, are resistant to ionizing radiation therapy
(Bao et al., 2006) and to temozolomide chemotherapy, the latter
at least partially due to high MGMT expression in hypoxic re-
gions (Persano et al., 2012). The ability of GSCs to direct glioma
growth and evade therapy depends on their cooption of specific
canonical stem cell signaling pathways, including Notch, WNT,
and Shh (Clement et al., 2007; Wang et al., 2010), by which
they acquire programs of self-renewal, propagation, and thera-
peutic resistance (Sengupta et al., 2012). A rational strategy to
treat GBMwould be to therapeutically target pathways on which
GSCs depend (Felsher, 2010).
Cyclin-dependent kinase 5 (CDK5) is an unconventional Cdk
that regulates developmental and adult neurogenesis, as well
as cell survival in post-mitotic neurons (Lagace et al., 2008). In
the brain, CDK5 normally remains inactive until it binds with its
partners P35 and/or P39 (Shah and Lahiri, 2014). Aberrant
CDK5 activity plays a critical role in the growth and propagation
of multiple forms of cancers (Pozo et al., 2013; Yushan et al.,
2015). CDK5 is highly expressed in GBM (Yushan et al., 2015),
possibly due to its location on chromosome 7, which is one
of the most frequent sites of copy number gains in primary
(isocitrate dehydrogenase [IDH] wild-type) GBM (Ozawa et al.,
2014). In this study, we present CDK5 as a promoter of self-
renewal through its deregulation of asymmetric cell division in
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brain tumor stem cells, at least in part through its PKA/cyclic
AMP-independent phosphorylation and activation of CREB1.
We also show that antagonizing this CDK5-CREB1 pathway
suppresses both self-renewal of GSCs and glioma growth.
RESULTS
dCdk5 Is Overexpressed in Drosophila Brain Tumor
StemCells and Its Reduction Ameliorates TumorGrowth
In previous work, we established that Drosophila Brat and its hu-
man ortholog, TRIM3, regulate asymmetric cell division (Chen
et al., 2014; Mukherjee et al., 2016). Reduced TRIM3 in GBMs
is directly associated with glioma cell division and self-renewal.
We also previously established a brat-RNAi model in Drosophila
neuroblasts that generates brain tumors in adult flies (Mukherjee
et al., 2016) that are composed almost entirely of tumor stem
cells, are actively proliferating (Figure S1A), and have disrupted
asymmetric cell division properties (Mukherjee et al., 2016).
We next used the brat-RNAi system to generate eye tumors in
Drosophila, which produce a visible and non-lethal phenotype.
Genetic and phenotypic analysis of eye overgrowth phenotypes
have been successfully used to delineate oncogenic signaling
pathways such as RAS, Hippo, GSK3b, PTEN, and BMP2 (Gon-
zalez, 2013). To search for kinases that antagonize the tumor
stemcell phenotype and that could represent potential therapeu-
tic targets, we performed a genetic screen where we crossed
RNAi lines for specific kinase genes with ey-GAL4 > brat-RNAi
stock and determined the extent of reduction in the brat-RNAi
eye tumor in the progeny. In the initial screen of 29 genes
(Table S1), we identified Drosophila Cdk5 (dCdk5) (Figure 1A, v)
and its activation partner, dP35 (Figure 1A, iv) as potential candi-
dates, because their suppression by RNAi completely reversed
the Drosophila brat-RNAi-mediated eye tumor phenotype (Fig-
ure 1A, ii). It is noteworthy that dCdk5 and dP35 knockdown in
normal eye, in the absence of brat-RNAi, does not result in a
phenotype (not shown). From these results, we hypothesized
that dCdk5 may act as an oncogene that promotes CNS tumor
growth. To investigate this further, we examined dCdk5 protein
expression and distribution inbrat-RNAi-mediated adult brain tu-
mors, which are characterized by dominant population of stem
cells that express the marker Mira (Miranda). We found that this
brain tumor stem cell population strongly and specifically ex-
press activated phospho (Y15) dCdk5 (Lin et al., 2007) (Figure 1C,
i and ii), while other cells did not.We next askedwhether the sup-
pression of dCdk5 or its partner, dP35, could reverse the brat-
RNAi brain tumor phenotype that is caused by disrupted asym-
metric cell division. Indeed, dp35-RNAi and dcdk5-RNAi both
markedly reduced the proliferation of tumor stem cells (phos-
phorylated histone 3 [PH3], in white) (Figures 1C, iv and v, and
S1B) and the number of cells expressing the stem cell marker
Mira (in green) (Figures 1C, vii and viii, and S1C). The tumor vol-
ume itself was considerably reduced (Figure 1C, vii and viii),
although the rescues were incomplete. These experiments es-
tablished that dCdk5 and dP35 regulate cell proliferation and
self-renewal properties of Drosophila brain tumor stem cells.
CDK5 Overexpression Deregulates Asymmetric Cell
Division of Drosophila Neuroblasts
Drosophila neuroblasts normally divide asymmetrically, where
after division one daughter cell keeping its self-renewal proper-
ties and expressing Mira and the other Mira-negative daughter
cell losing the ability to self-renew (Figure 1D, i). Because sup-
pression of dCdk5 had the capacity to suppress brat-RNAi tumor
stem cell proliferation (Figure 1C, v), we hypothesized that the
CDK5 signaling pathway might also regulate asymmetric cell di-
vision. To test this, we first suppressed dCdk5 using the RNAi
system in neuroblasts with the inscuteable-GAL4 driver. We
observed more than 50% reduction of the stem cell marker
Mira (Figures 1D, iv, and S1G) and a high expression of neuronal
cell marker ElaV in these cells. Drosophila neuroblasts normally
do not express ElaV. However, dCdk5 suppression in these cells
using two different RNAi lines (Bloomington Stock Center),
showed neuronal differentiation (Figures S2A and S2B). We
then investigated if increased CDK5 signaling deregulates the
neuroblast self-renewal process by taking advantage of the hu-
man CDK5-overexpressing transgenic fly line (Zografos et al.,
2016). The CDK5 protein sequence has 79% identity to dCdk5,
and the human CDK5 activator protein P35 (CDK5R1) has 66%
identity with dP35 (Figure 1B). OverexpressedCDK5 in fly neuro-
blasts greatly disrupted self-renewal. We saw a large accumula-
tion of neuroblasts, as confirmed by the aberrant expression of
Mira (Figure 1D, vii), which is typically lost following asymmetric
division, when daughter cells generate differentiated neurons or
glia. We also observed significant loss of ElaV, which most likely
Figure 1. CDK5 Regulates Self-Renewal and Asymmetric Cell Division in Drosophila Neuroblasts
(A) Drosophila eye screen. (i) Drosophila normal eye. (ii) brat-RNAi using eyeless-GAL4 drives overgrowth of the eye. Using this phenotype, we performed a
suppressor screen for kinases and found that reducing dcdk5 (v) and its activating partner, dp35 (iv), can reverse the overgrowth successfully. Suppression of two
other kinases, dS6k (iii) and dEip63E (vi), did not revert the overgrowth completely. Graphs of the suppressor screen experiments show statistical significance.
(B) Diagrams represent Drosophila P35 and Cdk5 are identical to human P35 (CDK5R1) and human CDK5 by 66% and 79%, respectively.
(C) brat-RNAi adult brain tumor shows high Mira expression (green) (i), indicating deregulated asymmetric division that generated these tumor stem cells. These
cells also express high levels of active dCdk5 (white) (ii) compared with normal cells. RNAi suppression of dP35 and dCdk5 in brat-RNAi tumors reduced cell
proliferation (PH3 staining, white) (iii, iv, and v) and the self-renewal marker (Mira, green) (vi, vii, and viii). Statistics are in Figure S1.
(D) We tested the potency of Cdk5 as an asymmetric cell division regulator by knocking down dCdk5 and by overexpressing human CDK5 specifically in
neuroblasts. During asymmetric division, larval neuroblast mother cells (Mira positive, green) generate progenitors that are Mira negative and eventually
differentiate (i, ii, and iii). Knock down of dCdk5 using RNAi specifically in neuroblasts reduced Mira expression without any visible change in daughter cells (red)
(iv, v, and vi). However, ectopic expression of hCDK5 in neuroblasts disrupted the asymmetric division, generating more Mira-positive cells (vii, viii, and ix).
Statistics are in Figure S1.
(E) CP681301, a specific CDK5 inhibitor, was fed to adult flies with brat-RNAi tumors. After 10 days of feeding, adult tumors lost expression of stem cell markers
(Mira, green) (i and ii) and active phosphorylated dCdk5 expression (white) (iii and iv).
(F) Suppressing dCdk5 activity with CP681301 increased the median survival of the brat-RNAi tumor-carrying flies by 2.85-fold. p < 0.0001.
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Figure 2. High CDK5 mRNA and Protein Expression and Close Association with Stem Cell Markers in GBM
(A) Most (82.8%) GBMs have high CDK5 gene copy number compared with 14.6% in LGGs.
(B) Comparing IDH1 wild-type LGGs and GBMs, we found that GBMs have high CDK5 mRNA expression.
(C) Immunohistological staining of LGG and GBM tumor tissues shows high CDK5 protein expression, correlating with mRNA data.
(D) We further investigated four patient-derived GBM neurosphere lines and found that they all express high levels of CDK5 and p35/25 proteins compared to the
control NHNP cells. These neurosphere lines also express high levels of OLIG2 and SOX2, two important stem cell markers.
(E) Examination of TCGA RNA-seq RSEM data using similarity matrix analysis revealed that mRNA expressions of CDK5 and CDK5R1 (p35) positively correlate
with stem cell and asymmetric cell division markers and negatively correlate with differentiation markers.
(legend continued on next page)
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indicates that neuroblast proliferation is occurring at the expense
of their differentiation (Figures S2A and S2B). Thus, our data sug-
gest that elevated levels of CDK5 can deregulate the asymmetric
division process, shifting toward more neuroblast generation.
We next tested whether a CDK5 inhibitor could suppress the
self-renewal properties of Drosophila brat-RNAi brain tumor
stem cells. We collected 0- to 2-day-old adult Drosophila
harboring brat-RNAi tumors and fed them a highly specific
CDK5 inhibitor (CP681301, 1 mM; Pfizer). We observed that
CP681301 reduced active phospho-dCdk5 (Y15) (white) in tumor
cells (Figures 1E, iii and iv, and S1E) after 10 days of feeding and
reduced the self-renewal properties of stem cells as shown by
the absence of Mira (green) (Figures 1E, i and ii, and S1D).
CP681301 also increased the expression of neuronal marker
ElaV in these cells, showing that in flies, dCdk5 inhibition causes
differentiation (Figure S1F). Finally, we measured the lifespan of
flies with tumors and found that CP681301 increased themedian
survival by 2.8-fold, although the tumors remained fatal (Fig-
ure 1F). Together, these data indicate that CDK5 acts as an
oncogene in fly tumors by deregulating asymmetric division
and promoting stemness, and that CDK5 inhibition can amelio-
rate the self-renewal capacity of tumor stem cells in flies. Our
data also showed that Drosophila and human CDK5 proteins
are highly conserved, even though the organisms are taxonom-
ically distant.
CDK5 Is Overexpressed in GBMs and CDK5 Knockdown
Reduces the Expression of Self-Renewal Genes in GSCs
The substantial homology between Drosophila and human
CDK5, as well as the evidence that dCdk5 regulates self-renewal
in Drosophila brain tumor stem cells and neuroblasts, led us
to investigate CDK5 for parallel functions in patient-derived
GBMs. Our analysis of the complete lower grade glioma (LGG)
and GBM data from The Cancer Genomic Atlas (TCGA) revealed
that CDK5 is frequently amplified in GBM (83%) and to a greater
degree than in LGGs (15%) (Figure 2A). Moreover, CDK5mRNA
expression is significantly higher in GBMs than in LGGs (Fig-
ure S3A). LGGs and GBMs are now classified based on the mu-
tation status of isocitrate dehydrogenase 1/2 (IDH1/2). The large
majority of GBMs are wild-type for IDH, whereas most LGGs are
IDHmutants. We found that CDK5mRNA expression was signif-
icantly higher in only the GBMs (Figure 2B) compared to the
IDH wild-type LGGs, but similar among IDH mutant GBMs and
LGGs cases (Figure S3B). Some of these differences in CDK5
expression are likely due to frequent copy number gains of chro-
mosome 7 in IDH wild-type GBMs, but not in IDHmutant GBMs,
in agreement with previous findings that CDK5 is one of the few
amplified genes on chromosome 7 that correlates with high
mRNA expression (Ozawa et al., 2014).
To determine if a high level of CDK5 mRNA corresponds to
elevated CDK5 protein expression, we first performed immuno-
histochemistry on institutional GBM and LGG tissue samples
and found that CDK5 was highly expressed in GBMs compared
to LGGs (Figure 2C). We next examined CDK5 and hP35
(CDK5R1) protein expression in cultured, patient-derived GBM
cells grown as neurospheres and found that they were both ex-
pressed at higher levels than normal human neural progenitor
cells (NHNPs) (Lonza) (Figure 2D). GBM neurosphere lines also
highly expressed the self-renewal proteins SOX2 and OLIG2
(Suva` et al., 2014; Tre´pant et al., 2015) (Figure 2D).
Based on our finding in Drosophila neuroblasts and brain
tumor stem cells (Figures 1 and S1A), we hypothesized that
CDK5 may directly regulate GSC properties promoting growth
and maintenance of GBMs. To test this, we first established in
a similarity matrix analysis that CDK5 and CDK5R1 expressions
are correlated with the expression of self-renewal SOX2, OLIG2
(Suva` et al., 2014; Tre´pant et al., 2015), PROM1 (CD133) genes,
and apically localized asymmetric cell division markers,
NOTCH1, PARD6A, PROM1 (CD133), and GPSM2 (LGN) genes
in GBM samples from the TCGA RNA sequencing (RNA-seq)
and the U133 microarray data. We also showed that CDK5
and CDK5R1 are negatively correlated with the differentiation
markers GFAP, GALC, APOE, and basally localized asymmetric
cell division marker NUMB (Figures 2E and S3C). In particular,
correlations between CDK5 and SOX2 (p < 0.0001) and OLIG2
(p < 0.0001) were extremely strong (Figure S3D). To determine
if these TCGA results obtained from bulk tumor samples were
also valid in a pure GSC population, we separated GSCs
and non-GSCs from two patient-derived neurosphere lines
(GBM121 [no EGFR amplification] and GBM39 [EGFRvIII]),
based on CD133 and CDK5 expression. Although GSCs did
not show a higher level of CDK5 protein than non-GSCs (Figures
2F, S3E, and S3F), they had greater expression of active phos-
pho-CDK5 protein (Y15) (Figures 2F, S3E, and S3F) and self-
renewal markers (CD133 and OLIG2) (Figure 2F). To address
whether CDK5 can regulate self-renewal markers in GSCs, we
knocked down CDK5 using CDK5 small interfering RNA (siRNA),
which reduced both SOX2 and OLIG2 (Figure 2G). These data
suggest that CDK5 could be a regulator of self-renewal proper-
ties of GBMs, much like dCdk5 in Drosophila neuroblasts.
CDK5 Inhibitor CP681301 Inhibits GSC Self-Renewal
Based on these results, we hypothesized that CDK5 is funda-
mental for the self-renewal properties of GSCs and tested two
pharmacologic CDK5 inhibitors, including Roscovitine and the
recently developed compound CP681301, for their effects on
viability and stem cell properties. First we tested Roscovitine, a
purine derivative well-known CDK5 inhibitor, on neurosphere
lines and the MTT assay revealed that it is cytotoxic at 20 mM
concentration (Figure S3G). Roscovitine also suppressed the
expression of stem cell markers at earlier time points (Fig-
ure S3H). Several studies, however, have shown that Roscovi-
tine can also inhibit CDK1, CDK2, CDK7, and CDK9 in addition
to CDK5 (Yin et al., 2015). CP681301, on the other hand, has
(F) To see if our data can reflect the TCGA data, we used FACS to isolate GSCs based on CD133 expression. We found that total CDK5 and activated phos-
phorylated CDK5 (pCDK5-Y15) expression is high in GSCs.
(G) To see whether CDK5 can regulate self-renewal markers in GSCs, we knocked down CDK5 using CDK5 siRNA and found that stem cell markers such as
OLIG2 and SOX2 downregulated. **p < 0.01, ****p < 0.0001.
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Figure 3. CDK5 Regulates Self-Renewal Properties in GSCs
(A) To determine if CDK5 regulates self-renewal of GSCs, first we tested the potency of a highly specific CDK5 inhibitor called CP681301 from Pfizer. Using active
CDK5-p35 and CDK5-p25 as enzymes, we established a dose-response curve for CP681301 in order to find the doses that successfully inhibit kinase catalytic
activity of both protein complexes in vitro. 1 mMCP681301 was the optimal concentration that suppressed 100% of CDK5-p35 and CDK5-p25 catalytic activity.
(B) CP681301 (1 mM) for 96 hr is significantly less toxic to NHNPs (control) than GSCs. *, <0.05, ***, <0.001, ****, <0.0001.
(legend continued on next page)
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been developed as a CDK5 inhibitor with much greater speci-
ficity (Pozo et al., 2013). Activation of CDK5 depends on its bind-
ing with P35, a 35 kDa molecular weight protein. The CDK5-P35
complex is largely distributed in the perinuclear region and at the
plasma membrane (Shah and Lahiri, 2014). Studies have shown
that CDK5-P35 binding is unstable and that P35 can be cleaved
by calpain into a smaller fragment called P25, which results in a
more stable CDK5-P25 complex that localizes to both the
cytosol and nucleus (Kusakawa et al., 2000). Both CDK5-P35
and CDK5-P25 show kinase activity (Shah and Lahiri, 2014). To
determine if the CDK5 inhibitor CP681301 can suppress the
kinase activity of both of these complexes, we tested the drug
in a range of concentrations starting from 0.1 nM to 1 mM. Our
results showed that CP681301 completely abolished activities
of both CDK5-P35 and CDK5-P25 at a concentration of 1 mM
(Figure 3A).
Next, we tested the cytotoxic effect of CP681301 on GBM
neurosphere cultures and NHNPs (normal human neuro-progen-
itors) in order to determine if there was differential toxicity among
neoplastic and non-neoplastic cells. We found that 1 mM was
variably cytotoxic to the tested GSC cultures but was not toxic
to NHNPs at 96 hr (Figures 3B and S3I). We also found that treat-
ment of GSCs with CP681301 for 48 hr moderately suppressed
the expression of CDK5 total protein but had a more marked
suppressive effect on the tyrosine-15 (Y15) phosphorylation sta-
tus, which is associated with CDK5 kinase activation (Figure 3C)
(Zukerberg et al., 2000). As mentioned, CP681301 is more spe-
cific to CDK5 than its closest relative CDK2, whose phosphory-
lation and activation is not affected in these cells upon 1 mM
CP681301 treatment (Figure S4A). Interestingly, the inactivation
of CDK5 by CP681301 was also associated with a reduction
of the stem cell markers CD133, OLIG2, and SOX2 (Figure 3C)
and the cell proliferation marker Ki67 (Figure 3C), but did
not change GFAP and TUJ1 expression upon differentiation
conditions (Figures 3C, S4B, and S4C). However, we have not
completely ruled out that other lines of differentiation, such as
oligodendrocytes, may occur.
To examine the effects of CDK5 inactivation by CP681301 on
GSC self-renewal function, we tested the neurosphere formation
using the extreme limiting dilution assay (ELDA) (http://bioinf.
wehi.edu.au/software/elda/) (Hu and Smyth, 2009) and found
that sphere formation rate is dramatically suppressed within
72 hr (Figure 3D). We performed the ELDA onGSCs after treating
them with CDK5 siRNA for 72 hr. The results also show signifi-
cant reduction in self-renewal under low CDK5 (Figure S5E).
We also performed a visual primary sphere formation experiment
in the absence and presence of CP681301 for 96 hr and found
that even at early time points, the rate of sphere formation drops
down from 77.87% to 52.31% in GBM121 GSCs and from
77.93% to 53.88% in GBM39 GSCs (Figure 3E). In these same
cell lines with reduced sphere formation, we also showed that
drug treatment was associated with reduced CDK5 phosphory-
lation, as well as OLIG2 and SOX2 expression (Figures 3F and
S5A–S5C).
CP681301 Reduces Cell Proliferation in Xenograft
Tumors but Not Normal Brain Tissue
After observing the effect of CP681301 on GBM121 and GBM39
GSCs in vitro, we generated xenograft orthotopic tumors in NSG
mice.Weorthotopically injected13105GSCs fromGBM121and
GBM39 into mouse brains and allowed them to grow for
2 months, at which time they measured from 0.3–0.4 mm (Fig-
ure 4A). We then removed the brains and established ex vivo or-
ganotypic explant slice cultures (300-mm) to directly observe gli-
oma growth dynamics and the expression of stem cell markers in
the presence of 0, 10, or 50 mMCP681301. After 48 hr, CP681301
reduced the phosphorylation of CDK5 as well as the expression
of the proliferation marker Ki67 (Figure 4B). Western blot data
also showed reduced expression of the stem cell markers
CD133, SOX2, and OLIG2 (Figures 4C and S5H–S5J). We also
tested the contralateral brain hemispheres (without neoplastic
cells) and found that CP681301 did not affect the viability of
normal tissue or affect cell self-renewal markers or active CDK5
status (Figure S5G). On H&E and immunohistochemical stains,
we did not see evidence of neurodegeneration, cell proliferation
(Ki67) or increased expression of phospho-CDK5 and phos-
pho-CREB1 (not shown). Together, these data indicate that
CP681301 reduces CDK5 activation, stem cell marker expres-
sion, and cell proliferation in mouse xenografts ex vivo.
CDK5 Activates the Self-Renewal Regulator CREB1
in GSCs
To determine the downstream pathways by which CDK5 regu-
lates the self-renewal properties of GSCs, we examined the
expression and activation of established self-renewal and prolif-
eration-related oncogenic proteins, retinoblastoma (RB), c-MYC,
and cAMP response element binding protein 1 (CREB1), in pres-
ence and absence of CP681301.We found that the phosphoryla-
tion of RB (Ser807/811) and CREB1 (Ser133) (Figures S6A and
S6B) were reduced following CDK inhibition (Figure 4D). Activa-
tion of CREB occurs by Serine 133 phosphorylation (Mayr and
Montminy, 2001) andourwestern blot and immunocytochemistry
data (Figures 4H and S5D) indicates CDK5 activates CREB1 in
this manner. To determine which of these CDK5 targets were
most likely to regulate self-renewal properties in GBMs, we
examined the correlation between RB, c-MYC, and CREB1 with
four induced tumor-propagating cell (iTPC) transcription factors,
SOX2, OLIG2, SALL2, and POU3F2 (Suva` et al., 2014), using
RNA-seq data from TCGA. Among these, we found that CREB1
correlated most strongly with all four transcription factors,
compared to c-MYC and RB (Figure 4G). Additionally, CDK5
also correlated with CREB1 in U133 microarray data (p < 0.001)
(Figure 4E). Our similarity matrix analysis of TCGA RNA-seq
data revealed that CREB1 is directly correlated with all iTPC
(C) CP681301 treatment for 48 hr suppressed active CDK5 and reduced stem cell markers CD133, OLIG2, and SOX2 and cell proliferation marker KI67 in GSCs
but did not change differentiation markers (GFAP).
(D and E) Using a limiting dilution assay (D) and visual demonstration (E), we established that CP681301 also reduces the self-renewal properties of GSCs.
(F) Immunocytochemistry showed that GSCs from two neurosphere lines have reduced levels of active CDK5 and stem cell markers SOX2 andOLIG2 (Figure S6).
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Figure 4. CDK5 Inhibitor Suppresses Self-Renewal and Proliferation of GBM Xenograft Tumors in Explant Cultures
(A) Diagram shows the mice xenograft tumor implantation and explant culture flow chart. Two months after implantation, GBM121 and GBM39 both produce
considerably large tumors on the right side of the brains.
(B) Tumor sections (300 mm)were cultured onPetri dishes for 48 hr with 0, 10, and 50 mMCP681301. Immunohistochemical analysis shows significant reduction of
active CDK5 and Ki67 staining in the tumor in cultures sections treated with CP681301 relative to control.
(C) Western blots performed on protein lysates created from xenografted tumors show downregulation of stem cell markers and confirm suppression of CDK5
phosphorylation through ABL and cell proliferation (Ki67).
(D) Investigating putative downstream targets of CDK5, we found that phosphorylated (p)-RB (inactive RB), p-MYC (active MYC), and p-CREB1 are all sup-
pressed by CP681301 treatment.
(E) Among these, the expression of CREB1 and CDK5 are strongly correlated in TCGA U133 GBM data.
(legend continued on next page)
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transcription factors but is negatively correlated with differentia-
tion markers (Figure 4F). We further examined the promoters of
these iTPC transcription factors usingPatch1.0 transcription fac-
tor binding predictor software and found that the predicted pro-
moter regions (1,000 bases upstream of the coding region) of
all four factors found from Eukaryotic Promoter Database of
Swiss Institute of Bioinformatics contain at least one full CRE
motif for CREB1 binding, whereas only OLIG2, SOX2, and
SALL2 promoters have c-MYC binding sites (Figure S6E). We
also used JASPER transcription factor motif predictor and found
that all thesepromoter regions havemultipleCREB1binding sites
(Table S2). Finally, we verified our analysis using CREB Target
(F) Additionally, TCGA RNA-seq RSEM data showed that CREB1 is positively correlated with iTPC transcription factors SOX2, OLIG2, SALL2, and POU3F2.
(G) Analysis of TCGA RNA-seq RSEM data also showed that CREB1 is strongly correlated with all four of these transcription factors, whereas MYC is only
correlated with two of these.
(H) Immunocytological data also supports that CDK5 inhibition reduces CREB1 phosphorylation. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Figure 5. CDK5 Directly Binds to and Phos-
phorylates to Activate CREB1 in GSCs
(A) CP681301 treatment of mice xenografted
explant culture tumors induced a clear down-
regulation of CREB1 phosphorylation.
(B) Western blot data using these tumor tissues
also show downregulation of CREB1 phosphory-
lation.
(C) We then investigated the mechanism by which
CDK5 regulates CREB1. We found that Cdk5 can
directly bind with CREB1, and CP681301 reduces
the binding of CDK5 to CREB1.
(D) An in vitro kinase assay showed that CDK5
can phosphorylate CREB1 at serine 133, and
CP681301 can suppress this phosphorylation in a
dose-dependent manner.
(E) Diagram showing our proposed model where
CDK5 directly phosphorylates and activates
CREB1 without the requirement of cAMP/PKA
in GSCs.
Gene Database from Salk and using
Human CRE prediction portal (http://
natural.salk.edu/CREB/). We found that
three out of four transcription factors
(OLIG2, SOX2, and POU3F2) have cAMP
response element (CRE) sites (Zhang
et al., 2005). In addition to activating
CREB, we also found that pharmacolog-
ical suppression of CDK5 could downre-
gulate the expression of potential CREB1
target genes, such as SOX2 and OLIG2
(Figure 4C).
We next tested CP681301 for its effects
on CREB1 in ex vivo xenograft organo-
typic cultures by immunohistochemistry
and western blotting and found that
CREB1 phosphorylation was substan-
tially suppressed after treatment (Figures
5A and 5B). Finally, in order to find the
specific effect of CREB1 on GSCs self-
renewal programs, we knocked down CREB1 using siRNA,
which resulted in the reduction of self-renewal behavior
measured by ELDA (Figure S5F) and expression of critical self-
renewal transcription factors, including OLIG2, POU3F2, and
SALL2, indicating that CREB1 indeed regulates stem cell pro-
grams in GSCs (Figure S6C). To determine how CDK5 regulates
CREB1, we performed a co-immunoprecipitation (coIP) assay
and found that CREB1 pulled down CDK5 (Figure 5C). This is a
step forward on the existing knowledge, because previous
studies have suggested that signal transduction intermediaries,
such as protein kinase A (PKA), mediate activation of CREB by
CDKs in neurons in dopaminergic neurotransmission (Zhong
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et al., 2014). To determine whether CDK5 can form complex with
and can phosphorylate CREB1 in the absence of cAMP and
PKA, we performed an in vitro kinase assay using only recombi-
nant active CDK5-P35 and CDK5-P25 with recombinant CREB1
as a substrate. The results clearly show that both CDK5-P35 and
CDK5-P25 phosphorylated CREB1 (Figure 5D). We used Tau, an
established substrate of CDK5, as a control (Figure S6D). We
also established that CP681301 (0.5 mM and 1 mM) was capable
of suppressing CREB Ser133 phosphorylation by CDK5 (Fig-
ure 5D), similar to in situ GSC data.
CDK5 Expression Segregates with
Non-mesenchymal GBMs
The finding that CDK5 may regulate self-renewal properties
in GSCs by directly phosphorylating CREB independently of
Figure 6. Expression Profile of CDK5 and
Stem Cell Genes Segregate in Non-mesen-
chymal GBMs
(A) Using TCGA RNA-seq RSEM data, we exam-
ined whether the expression ofCDK5,CDKR1, and
CREB1, along with the self-renewal and asym-
metric cell division marker genes, have a clinical
significance. Unsupervised hierarchical clustering
analysis indeed show that a majority of the
non-mesenchymal GBMs (cluster 1) express high
levels of these genes, whereas mesenchymal
GBMs have high expression of differentiation
markers (cluster 2).
(B) Our detailed analysis showed that 62.96%
of non-mesenchymal tumors fall in cluster 1
(p < 0.001), whereas 83.33% of mesenchymal
tumors fall in cluster 2 (p < 0.001).
PKA/cAMP opens further avenues of in-
quiry, with potential clinical significance.
To determine relevance to specific mo-
lecular subtypes of GBMs, we performed
an unsupervised clustering analysis on
data available from TCGA related to the
self-renewal and asymmetric cell division
markers, as well as CDK5, CDK5R1, and
CREB1. Using most recent classification
of GBM including neural, classic, and
mesenchymal subtypes (Wang et al.,
2018), our analysis of TCGA RNA-seq
RSEM data from 129 patients revealed
an interesting dichotomy, in which the
majority of non-mesenchymal tumors
(75.64%) were associated with high
expression of CDK5, CDK5R1, CREB1,
and self-renewal and asymmetric cell
division markers, whereas the majority
of the mesenchymal GBM subtypes
(80.39%) showed high expression of
differentiation markers (Figures 6A and
6B). These data suggest an enhanced
stem cell signature in non-mesenchymal
forms of GBM in which is self-renewal
makers are expressed to a greater extent than in the mesen-
chymal subtype.
DISCUSSION
The roles of CDK5 in neurogenesis and in support of post-mitotic
neuronal survival have been established for more than two de-
cades, yet its potential influence on stem cell regulation is less
clear (Hellmich et al., 1992; Smith-Trunova et al., 2015). In a pre-
vious study, when floxed cdk5was excised by estrogen-induced
nestin-driven Cre specifically in mice adult hippocampal subgra-
nular neural stem cells, these cells failed to grow, suggesting that
CDK5 has a fundamental role in regulating stem cell division and
survival in the brain (Lagace et al., 2008). Considering the diverse
targets of CDK5, such as RB, MYC, as well as Drp1 (Xie et al.,
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2015), CDK5 is likely to be one part of this complex self-renewal
signaling network. Our current findings indicate that CDK5 is
more deeply involved in regulating self-renewal properties by
directly regulating CREB pathway and its downstream signaling
network in GSCs.
Our investigation using Drosophila brain tumor stem cells and
human GSCs establishes a direct role of CDK5 signaling in the
regulation of self-renewal properties and asymmetric division.
Asymmetric cell division is a central property of neural stem cells
and the canonical pathways that control this delicate process in
Drosophila neuroblasts have been well established (Egger et al.,
2011; Knoblich, 2010). However, the impact of CDK5 on these
pathways has not been explored. Our results showed that
dCdk5 and human CDK5 could promote fly brain tumor stem
cells and GSCs generated from deregulated asymmetric cell
division, clearly indicating that CDK5 regulates self-renewing
division in these populations.
In evaluating how CDK5 maintains the self-renewal properties
that promote the proliferation and growth of GSCs, we found that
CDK5 directly binds to and activates CREB1, a transcription fac-
tor with established significance in many cancer types, including
breast cancer, leukemias and lymphomas, colorectal cancer,
and glioma (Daniel et al., 2014), also reviewed in the Human Pro-
tein Atlas (Uhle´n et al., 2005). Our analysis of TCGA data also
shows that CREB1 correlates with the tumor-propagating cell
transcription factors SOX2, OLIG2, SALL2, and POU3F2, each
of which contains CREB1 binding sites in their promoters. Phos-
phorylation and activation of CREB1 has previously been shown
to be dependent on cAMP (hence the name, cAMP response
element binding protein) and PKA (Gonzalez and Montminy,
1989). cAMP levels regulate a variety of signaling pathways,
including as PKA, p38, and MEK/ERK (Arthur and Cohen,
2000; Fujita et al., 2002; Grewal et al., 2000; Wiggin et al.,
2002; Xing et al., 1996), which, in turn, control CREB1 activation.
Our data indicate that CDK5, which has previously been shown
to activate CREB1 through cAMP/PKA in dopamine neurons
present in the ventral tegmental area (Zhong et al., 2014), can
directly bind with and phosphorylate CREB1 in a PKA/cAMP-
independent manner, at least in GSCs.
In gliomas, CREB regulates cell proliferation through (1) acti-
vating cyclin D1, cyclin B1, and PCNA, and residing downstream
of ERK and AKT pathways (Sampurno et al., 2013) and (2) EGFR
and PDGFR signaling (Mantamadiotis et al., 2012). Cell prolifera-
tion through CREB phosphorylation can also be induced by the
absence of PTEN in a PI3K/AKT independent fassion (Gu et al.,
2011). Our analysis of TCGA patient data shows that CREB is
highly expressed in GBMs and positively correlated with CDK5
expression, supporting our finding that they are within the same
pathway. Nuclear activated phospho-CREB seen by immunohis-
tochemistry, a strong correlation between CREB and iTPC tran-
scription factors and the suppression of stem cell markers with
CREB downregulation support the notion that CREB regulates
self-renewal properties in GSCs. CREB regulates proliferation
of neural stem cells, both in the developing brain across taxa
(Mantamadiotis et al., 2012) and in the neurogenic zones of the
adult vertebrate brain (Mantamadiotis et al., 2012). Given the
fact that CREB activation is essential in initiating stem cell prolif-
eration, it is not surprising thatGSCscoopt this signalingpathway
for enhancing self-renewing division. Thus, suppression of CREB
can pacify the growth and proliferation of these cells, corrobo-
rating previous findings (Mantamadiotis et al., 2012).
GBMs and LGGs have now been well characterized and
molecularly classified (Brat et al., 2015; Ceccarelli et al., 2016).
Our analysis of TCGA data confirms higher CDK5 expression in
GBM than in LGG (using the combined IDHwild-type andmutant
cases), which likely corresponds to frequent copy number gains
on chromosome 7 in GBM (Ozawa et al., 2014). Both IDH wild-
type LGG and GBM show frequent gains of chromosome 7, but
because CDK5 mRNA expression is more highly expressed in
GBMs, other factors critical to aggressive behavior, such as the
development of hypoxia and necrosis,maycause further upregu-
lation during disease progression. The associations ofCDK5with
stem cell and asymmetric cell division markers in GBM samples
support our mechanistic findings in Drosophila and mouse
models, as does the interesting finding of strong negative
correlationswith differentiationmarkers. Finally, an unsupervised
analysis of theGBMgene expression data showed that theCDK5
signaling pathway is highly enriched in non-mesenchymalGBMs,
suggesting that these mechanisms are likely more active in spe-
cific subsets that could be sensitive to targeted therapies.
In our current study, we found that CDK5 plays a substantial
role in the regulation of GSCs, adding to the findings of previous
studies that have suggested that CDK5 is important for the
growth of normal neural progenitors (Lagace et al., 2008). Using
CDK5 knock down experiments and a specific CDK5 inhibitor
CP681301, we established that GSCs are more sensitive to the
suppression of this pathway than normal neural stem cells, sup-
porting the conclusion that GSCs are more dependent on the
activation of stem cell programs directed by CDK5 through
CREB. This is an important finding, as targeting CDK5 signaling
to treat GBMs could potentially eliminate CDK5-addicted GSCs
and reduce the likelihood of recurrence.
EXPERIMENTAL PROCEDURES
All work with human cell lines aswell as animal models was done at Emory Uni-
versity. The protocols to use human cells in laboratories were approved by
Emory IRB and the use of animal models for the experiments was approved
by Emory Institutional Animal Care and Use Committee (IACUC).
Drosophila Stocks and Genetic Cross
All Drosophila stocks were maintained at 25C unless otherwise mentioned.
Inscuteable-GAL4, UAS-hCDK5, UAS-bratRNAi, eyeless-GAL4, UAS-p35RNAi,
UAS-cdk5RNAi, UAS-s6kaRNAi, UAS-Eip63ERNAi, and 26 other RNAi stocks
(Table S1) were obtained from Bloomington Drosophila Stock Center.
eyeless-GAL4; UAS-brat-RNAi viable stock carried eye tumor. Flies from
this stock were crossed with the RNAi lines tested. Eye tumor sizes were
scored between 4 and +4, where 0 was considered as normal eye. Mann-
Whitney U test was performed to find significance in the degree of rescue
for each gene. Approximately 50 flies were checked per gene.
p35 and cdk5 RNAi stocks were used to knockdown these gene’s expres-
sions in brat-RNAi brain tumor to see the rescue. At least 25 flies were tested.
UAS-Cdk5RNAi and UAS-hCDK5 stocks were used to test the effect of
CDK5 downregulation and upregulation in Drosophila neuroblasts. 3rd instar
Larvae were dissected and stained to check the changes in neuroblasts.
Drosophila Adult Brain Dissection and Staining
AdultDrosophilabrainswere dissected out in 13PBSbycarefully removing the
cuticle surrounding the brain. The brainwas fixedwith 4%paraformaldehyde in
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13 PBS for 90 min by end over end mixing. The fixed brains were washed with
0.5% Triton X-100 in 13 PBS for 30 min to 1 hr. Brains were then incubated for
2 days at 4C in primary antibody in 0.5% Triton X-100 in 13 PBS with 10%
BSA (antibody dilution buffer). After primary antibody incubation, brains were
washedwith 0.5%Triton X-100 in 13PBS3 times, 15min each. The secondary
antibodywas also diluted in antibody dilution buffer and incubated overnight at
4C. Finally, the brains were washed 3 times and added to Vectashield Dapi
(H-1200) (Vector Laboratories) mounting media and kept for 2 days in dark at
4C. The brains were finally mounted using Vectashield Dapi (H-1200)
mounting media. Primary antibodies are: Mira (Miranda) (1:200) (gift from
Dr. Cheng-yu Lee) and phospho-Cdk5 (1:200) (sc-12918-R) (Santa Cruz). Pic-
tures were taken using Olympus FV-1000 confocal microscope.
Drosophila Larval Brain Dissection and Staining
3rd instar larval brains were dissected out in 13 PBS, fixed in 4% parafor-
maldehyde. Staining was performed following the standard protocol
by Daul et al. (2010). Brains were finally mounted using Vectashield Dapi
(H-1200) (Vector Laboratories) mounting media. The primary antibody was
Mira (1:200). Pictures were taken using Olympus FV-1000 confocal
microscope.
Drosophila Drug Feeding and Lifespan Study
Drosophila adult flies between 0–2 days old were fed with the CDK5 inhibitor
CP681301 at 1 mM dilution in 100% ethanol spread on top of the food. Flies
were kept at 18C, and food was changed every other day. We keep the flies
at 18C to ensure that they get enough drug in their system before they perish
due to the tumor. The control foods carry the vehicle, 100% ethanol.
TCGA Data Analysis
DNA copy number alteration (CNA), RNA seq, and U133microarray TCGA data
were obtained from cBioPortal and Ceccarelli et al. (2016). Graph pad Prism
V6.0 was used to analyze the data and t test was performed to find out the
significance of the data. IDH1 WT and IDH1 mut GBM (glioblastoma) and
LGG (lower grade glioma) patients were selected manually.
Similarity Matrix Analysis
GBM RNA-seq and U133 microarray data from TCGA is used to generate
similarity matrix. Spearman correlation distance analysis was applied using
Morpheus online software from Broad Institute.
GBM Stem Cell Isolation
GBM39 (EGFR vIII-positive) and GBM121 (PDGFRA overexpression, no EGFR
amplification) neurospheres were separated using Accutase, stained with PE-
tagged CD133 antibody (Miltenyi Biotech) and CD133+ and CD133 cells were
sorted through fluorescence-activated cell sorting (FACS) Aria 2.0 cell sorter.
Histology
Human GBM tissues and xenografted human tumor organotypic cultures were
subjected to 10% formalin fixation and paraffin embedded sections were
immune-stained. Mounted slides were observed using 203 magnification,
and pictures were taken using Luminera camera. Primary antibodies used:
CDK5 (1:200) (Santa Cruz), p-CDK5 (1:200) (Santa Cruz), p-CREB1 (1:100)
(Cell Signaling Tech), and KI67 (1:200) (Abcam).
Western Blot
Standard western blot protocol was used to test differentmarkers in GSCs and
in co-immunoprecipitation. Proteins were isolated from GSCs and 10% SDS
gels. Specific protein bands were visualized using chemiluminescent dye
West Pico. Primary antibodies used were CDK5 (1:1,000), p-CDK5 (Y15)
(1:1,000), OLIG2 (1:1,000) (Santa Cruz), CREB (1:1,000), p-CREB (1:1,000),
SOX2 (1:1,000), (Cell Signaling Tech), KI67 (1:2,000) (Abcam), and Tubulin
(1:10,000) (Developmental Studies Hybridoma Bank).
Co-immunoprecipitation
For co-immunoprecipitation experiments, CP681301 untreated and treated
GSCs were collected and were fixed with 1% paraformaldehyde and lysed us-
ing NP-40. The paraformaldehyde fixation cross-linked the proteins for co-
immunoprecipitation experiments. Co-immunoprecipitation was performed
using protein G Dynabeads (Thermo-Fisher). Finally, eluted lysate was heated
at 70C for 30 min to reverse the cross-link and to release the proteins from
their respective complexes. For the IP, we used CREB antibody and for detec-
tion, we used CREB, CDK5, and p35/25 antibodies.
In Vitro CP681301 Efficiency Test
Thermo Fisher Scientific tested the inhibitory efficiency of CP681301 on active
CDK5/P25 and CDK5/P35 in vitro. The Z’-LITE Kit was used to perform the
assay in a 384-well assay plate.
CDK5 Inhibitor Tests on GSCs
Two CDK5 inhibitors were tested on GBM121 and GBM39 GSCs. The
traditional Roscovitine was used at 20-mM concentration and Pfizer drug
CP681301 was used at 1-mM concentration and found to be effective. The
stock solutions were made in DMSO. The working solutions were made
diluting them in media. Cells were incubated for 48 hr in media with the inhib-
itors or with the DMSO only, and the results were obtained.
Extreme Limiting Dilution Assay
To perform extreme limiting dilution assay (ELDA), we seeded GSCs at 1, 20,
40, 60, 80, and 100 cells per well of 96-well plates. We used at least 24 wells
for each of the limiting dilution of GSCs. After 24 hr of plating the cells, we
added DMSO (vehicle) and CP681301 (CDK5 inhibitor). We counted the
number of wells with spheres at the end of the experiment. We performed
Chi-square statistical analysis using the following website: http://bioinf.
wehi.edu.au/software/elda/. On the x axis, the number of cell dilutions are
plotted. The y axis denotes ‘‘log fraction nonresponding.’’ The greater the
number of single cells present at the end of the experiment, the less self-
renewal is present, resulting in a more horizontal curve. When more cells
make spheres as a result of self-renewing division, the curve is steeper.
We tracked spheres up to 96 hr and took images of wells to demonstrate
the rate sphere formation.
Fluorescence Immunocytochemistry
For immunocytochemistry, we collected the GSCs as single cell suspension,
fixed them with 4% paraformaldehyde, and followed the protocol described
by Mukherjee et al. (2016). Primary antibodies include: p-CDK5 (Y15) (1:100),
OLIG2 (1:100) (Santa Cruz), p-CREB (1:100), and SOX2 (1:100) (Cell Signaling
Tech).
Mice Xenograft Tumor Generation
GSCs fromGBM121 andGBM39were collected based on their CD133marker
expression using flow cytometry. Cells were then injected at 1 3 105 concen-
tration at the right hemisphere of the neonatal NSG female mice. 10–12 mice
were used to inject each of the GSCs.
Organotypic Explant Culture
Mice brains with xenografted tumors were harvested in 13 sterile PBS. The
brains were cut into about 300 mM sections using vibratome. The sliced tumor
tissues and contralateral normal brains were added to porous membrane fed
with media from the bottom. The CDK5 inhibitor CP681301 was added in all
media at 0, 10 mM, and 50 mM concentration. The experiments were done
for up to 48 hr. The tissues are then collected and were subjected to both
histological staining and western blot analysis. 10–12 mice were tested for
each type of GSCs.
In Vitro Kinase Assay
Recombinant active CDK5/P25 and CDK5/P35 proteins (Millipore) were
used as enzymes. Active Tau protein (Anaspec: 55556-50) and active
CREB1 (Life Tech: 10074-H10E-5) proteins were used as substrates. The
in vitro kinase assay buffer, ATP (Cell Signaling Tech), and 0, 0.5 mM,
and 1 mM of CP681301 were added and mixed well. The reaction was incu-
bated at 30C for 30 min. Reaction was stopped by adding sample buffer
and heated to 70C for 10 min. Samples were kept at 20C until used in
western blot. Phosphorylation antibodies were used to detect the protein
band.
1662 Cell Reports 23, 1651–1664, May 8, 2018
siRNA Experiments
CDK5 andCREB1 siRNAswere received fromOrigene Technologies. 3 siRNAs
and one scrambled siRNA were transfected using Lipofectamine 3000 in
GBM121 and GBM39 GSCs. The cells were incubated for 72 hr and the pro-
teins were isolated and ran in western blot to visualize the effect of reduced
CDK5 and CREB1 on stem cell markers.
CREB Binding Site Determination on Promoters
To determine CREB binding sites on the promoters of OLIG2, SOX2, SALL2,
and POU3F2, we used Eukaryotic Promoter Database from Swiss Institute of
Bioinformatics (https://epd.vital-it.ch/cgi-bin/get_doc?db=hgEpdNew&format=
genome&entry=OLIG2_1). Using 500 bases upstream of the transcription start
site, we determined the presence or absence of CREB binding sites using
JASPER transcription factormotif database.We also usedPatch 1.0 online soft-
ware to find CREB binding sites. Finally, to ensure our claim, we used the CRE
prediction tool available from Marc Montminy lab of Salk institute.
Image Analysis
Image analyses was performed using ImageJ program.Wemeasured cell fluo-
rescence with this program and obtained the corrected total cell fluorescence,
where CTCF = integrated density – (area of selected cell3mean fluorescence
of background readings). We quantified the western blot band intensities
through densitometric analysis using ImageJ and normalized the band inten-
sities with the loading control band, such as Tubulin.
Statistics
To determine the significance of genetic rescue in our fly genetic screen, we
performed Mann-Whitney U test. For fluorescence image quantification and
densitometry analysis we performed parametric t test. For extreme limiting
dilution assay (ELDA), we performed Chi-square test.
Unsupervised Hierarchical Clustering Analysis
TCGA GBM samples with available RNA-seq gene expression data (Ceccarelli
et al., 2016; Wang et al., 2018) were analyzed (n = 129). Normalized RSEM
expression data were log2 transformed and patients were classified into
GBM subtypes: classical (n = 40), G-CIMP (n = 8), mesenchymal (n = 50),
and proneural (n = 28). Unsupervised hierarchical clustering was performed
for the genes of interest (CDK5, CDK5R1, stem cell markers, and differentia-
tion markers) using Euclidean distance and average clustering. Fisher’s exact
test was performed to test the association of the Heatmap clusters with GBM
subtypes. Heatmaps were generated using R 3.2.2 software.
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